Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G pTau 217 CSF Assay for Research Use Only

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE® G immunoassay analyzers. Th ...

Headsafe Enters U.S. Healthcare Market with FDA-Cleared Concussion Assessment Device

Lightweight portable system delivers fast, precise, objective data for rapid aid in diagnosis of concussions in ...
Nasdaq

BlinkLab Unveils AI-Powered Neurological Testing Platform

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...
Business Wire

Invitae Announces Major Expansion of Its Test Menu for Neurological, Pediatric, and Rare Genetic Conditions and Introduces New Panels for Inherited Metabolic Disorders and ...

SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...
Ophthalmology Times

IGS 2026: Considering OCT in neuro-ophthalmology and neurological diseases

At the 2nd International Glaucoma Symposium in Mainz, Germany, on 31 January 2026, optical coherence tomography (OCT) and its role in glaucoma and neuro-ophthalmic disease took centre stage in a ...